Proteomic profiling of cancer biomarkers

Briefings in Functional Genomics and Proteomics

Volumn 2, Issue 2, 2003, Pages 147-158

  Shau, Hungyi ^a   Chandler, G Scott ^a   Whitelegge, Julian P ^a   Gornbein, Jeffrey A ^a   Faull, Kym F ^a   Chang, Helena R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Analysis algorithm; Biomarkers; Cancer diagnosis; Matrix assisted laser desorption (MALDI); Proteomics; Surface enhanced loser desorption ionisation (SELDI)

Indexed keywords

PROTEOME; TUMOR MARKER; TUMOR PROTEIN;

CHEMISTRY; FEMALE; HUMAN; MALE; MASS SPECTROMETRY; METHODOLOGY; NEOPLASM; PROTEOMICS; REVIEW;

FEMALE; HUMANS; MALE; NEOPLASM PROTEINS; NEOPLASMS; PROTEOME; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 3242749915     PISSN: 14739550     EISSN: 14774062     Source Type: Journal    
DOI: 10.1093/bfgp/2.2.147     Document Type: Article

References (57)

1. Lacey, J. V. Jr, Devesa, S. S. and Brinton L. A. (2002), 'Recent trends in breast cancer incidence and mortality', Environ. Mol. Mutagen., Vol. 39, pp. 82-88.
2. Whitehouse, C. and Solomon, E. (2003), 'Current status of the molecular characterization of the ovarian cancer antigen CA 125 and implications for its use in clinical screening', Gynecol. Oncol., Vol. 88, pp. S152-157.
3. Whitehouse, C. M., Dreyer, R. N., Yamashita, M. and Fenn, J. B. (1985), 'Electrospray interface for liquid chromatographs and mass spectrometers', Anal. Chem., Vol. 57, pp. 675-679.
4. Fenn, J. B., Mann. M., Meng, C. K. et al. (1989), 'Electrospray ionization tor mass spectrometry of large biomolecules', Science, Vol. 246, pp. 64-71.
5. Tanaka, K., Waki, H., Ido, Y., et al. (1988), 'Protein and polymer analyses up to m/z 100,000 by laser ionization time-of-flight mass spectrometry', Rapid Comm. Mass Spectrom., Vol. 2, p. 151.
6. Karas, M. and Hillenkamp F. (1988), 'Laser desorption ionization of proteins with molecular masses exceeding 10.000 daltons', Anal. Chan., Vol. 60, pp. 2299-2301.
7. Laemmli, U. K. (1970), 'Cleavage of structural proteins during the assembly of the head of bacteriophage T4', Nature, Vol. 227, pp. 680-685.
8. Hutchens, T. W., Nelson, R. W. and Yip, T. T. (1991), 'Evaluation of peptide/metal ion interactions by UV laser desorption time-of-flight mass spectrometry', J. Mol. Recognit., Vol. 4, pp. 151-153.
9. Weinberger, S. R., Dalmasso, E. A. and Fung, E. T. (2002), 'Current achievements using ProteinChip Array technology', Current Opin. Chem. Biol., Vol. 6, pp. 86-91.
10. Pauling, L., Robinson, A. B., Teranishi, R. and Cary, P. (1971), 'Quantitative analysis of urine vapor and breath by gas-liquid partition chromatography', Proc. Natl Acad. Sci. USA, Vol. 68, pp. 2374-2376.
11. Matsumoto, K. E., Partridge, D. H., Robinson, A. B. et al. (1973), 'The identification of volatile compounds in human urine', J. Chromatogr., Vol. 85, pp. 31-34.
12. Posner, M. R. and Mayer, R.J. (1994), 'The use of serologic tumor markers in gastrointestinal malignancies', Hematol. Oncol. Clin. North Am., Vol. 8, pp. 533-553.
13. Macdonald, J. S. (1999), 'Carcinoembryonic antigen screening: pros and cons', Semin. Oncol, Vol. 26, pp. 556-560.
14. Duffy, M.J. (2001), 'Clinical uses of tumor markers: a critical review', Crit. Rev. Clin. Lab. Sci., Vol 38, pp. 225-262.
15. Rosenthal, A. N. and Jacobs, I.J. (1998), The role of CA 125 in screening for ovarian cancer', Int. J. Biol Markers, Vol. 13, pp. 216-220.
16. Smith, R. A., Cokkinides, V. and Eyre, H.J. (2003), 'American Cancer Society guidelines for the early detection of cancer, 2003', CA Cancer J. Clin., Vol. 53, pp. 27-43.
17. Small, E.J. and Roach, M. (2002), '3rd prostate-specific antigen in prostate cancer: A case study in the development of a tumor marker to monitor recurrence and assess response', Semin. Oncol., Vol. 29, pp. 264-273.
18. Pegram, M. and Slamon, D. (2000), 'Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy', Semin. Oncol., Vol. 27, pp. 13-19.
19. Liang, X., Smoller, B. R. and Golitz, L. E. (2002), 'Expression of CD44 and CD44v6 in primary cutaneous CD30 positive T-cell lymphoproliferative disorders', J. Cutan. Pathol., Vol. 29, pp. 459-464.
20. Akisik, E., Bavbek, S. and Dalay, N. (2002), 'CD44 variant exons in leukemia and lymphoma', Pathol. Oncol. Res., Vol. 8, pp. 36-40.
21. Press, O. W., Leonard, J. P., Coiffier, B. et al. (2001), 'Immunotherapy of Non-Hodgkin's lymphomas. Hematology', American Society Hematology Education Program, Washington, DC, pp. 221-240.
22. Yonezawa, S. and Sato, E. (1997), 'Expression of mucin antigens in human cancers and its relationship with malignancy potential', Pathol. Int., Vol. 47, pp. 813-830.
23. Finn, O. J., Jerome, K. R., Henderson, R. A. et al. (1995), 'MUC-1 epithelial tumor mucin-based immunity and cancer vaccines', Immunol. Rev., Vol 145, pp. 61-89.
24. Gendler, S.J. (2001), 'MUC1, the renaissance molecule', J. Mammary Gland Biol. Neoplasia, Vol. 6, pp. 339-353.
25. Duffy, M.J. (2001), 'Biochemical markers in breast cancer: Which ones are clinically useful?', Clin. Biochem., Vol. 34, pp. 347-352.
26. He, J., Shen, D. and O'Donnell, M. A. and Chang, H. R. (2002), 'Induction of MUC1-specific cellular immunity by a recombinant BCG expressing human MUC1 and secreting IL2', Int. J. Oncol, Vol. 20, pp. 1305-1311.
27. Zucker, S., Cao, J. and Chen, W. T. (2000), 'Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment', Oncogene, Vol. 19, pp. 6642-6650.
28. Baker, A. H., Edwards, D. R. and Murphy, G. (2002), 'Metalloproteinase inhibitors: Biological actions and therapeutic opportunities', J. Cell Sci., Vol. 115, pp. 3719-3727.
29. Johnson, P.J. (2001), 'The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma', Clin. Liver Dis., Vol. 5, pp. 145-159.
30. Labdenne, P. and Heikinheimo, M. (2002), 'Clinical use of tumor markers in childhood malignancies', Ann. Med., Vol. 34, pp. 316-323.
31. Riker, A. and Bartlett, D. (1999), 'Pancreaticoduodenectomy for chronic pancreatitis: A case report and literature review', Hepatogastroenterology, Vol. 46, pp. 2005-2010.
32. Menon, U. and Jacobs, I.J. (2000), 'Recent developments in ovarian cancer screening', Current Opin. Obstet. Gynecol., Vol. 12, pp. 39-42.
33. Berinstein, N. L. (2002), 'Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: a review', J. Clin. Oncol., Vol. 20, pp. 2197-2207.
34. Gordon, G.J. Jensen, R. V., Hsiao, L. L. et al. (2002), 'Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma', Cancer Res., Vol. 62, pp. 4963-4967.
35. Perou, C. M., Jeffrey S. S., van de Rijn, M. et al. (1999), 'Distinctive gene expression patterns in human mammary epithelial cells and breast cancers', Proc. Natl Acad. Sci. USA, Vol. 96, pp. 9212-9217.
36. Adam, B. L., Qu, Y., Davis, J. W. et al. (2002), 'Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men', Cancer Res., Vol. 62, pp. 3609-3614.
37. Zhang, Z., Page, G. and Zhang, H. (2001) 'Applying classification separability analysis to microarray data', in Lin, S. M. and Johnson, K. J., Eds, 'Methods of Microarray Data Analysis', Kluwer Academic Publishers, Norwell, MA, pp. 125-136.
38. Breiman, L., Friedman, J., Olshen, R. and Stone, C. (1984) 'Classification and Regression Trees', Wadsworth International Group, Belmont, CA.
39. URL: http://clinicalproteomics.steem.com/proteome-detail.php
40. Verma, M., Wright, G. L. Jr, Hanash, S. M. et al. (2001), 'Proteomic approaches within the NCI early detection research network for the discovery and identification of cancer biomarkers', Ann. NY Acad. Sci., Vol. 945, pp. 103-115.
41. Ahram, M., Best, C. J., Flaig, M.J. et al. (2002), 'Proteomic analysis of human prostate cancer', Mol. Carcinog., Vol. 33, pp. 9-15.
42. Wang, S., Diamond, D. L., Hass, G. M. et al. (2001), 'Identification of prostate specific membrane antigen (PSMA) as the target of monoclonal antibody 107-1 A4 by proteinchip; array, surface-enhanced laser desorption/ ionization (SELDI) technology', Int. J. Cancer, Vol. 92, pp. 871-876.
43. Wellmann, A., Wollscheid, V., Lu, H. et al. (2002), 'Analysis of microdissected prostate tissue with ProteinChip(R) arrays - a way to new insights into carcinogenesis and to diagnostic tools', Int. J. Mol. Med., Vol. 9, pp. 341-347.
44. Wright, G. L. J., Cazares, L. H., Leung, S. M. et al. (2000), 'ProteinChip Surface Enhanced Laser Desorption/Ionization (SELDI) mass spectrometry: A novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures', Prostate Cancer Prostatic Dis., Vol. 2, pp. 264-276.
45. Ardekani, A. M., Liotta, L. A. and Petricoin, E. F. 3rd (2002), 'Clinical potential of proteomics in the diagnosis of ovarian cancer', Expert Reu. Mol. Diagn., Vol. 2, pp. 312-320.
46. Petricoin, E. F., Ardekani, A. M., Hitt, B. A. et al. (2002), 'Use of proteomic patterns in serum to identify ovarian cancer', Lancet, Vol. 359, pp. 572-577.
47. Rosty, C., Christa, L., Kuzdzal, S. et al. (2002), 'Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology', Cancer Res., Vol. 62, pp. 1868-1875.
48. Li, J., Zhang, Z., Rosenzweig, J. et al. (2002), 'Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer', Clin. Chem., Vol. 48, pp. 1296-1304.
49. Paweletz, C. P., Trock, B., Pennanen, M. et al. (2001), 'Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: Potential for new biomarkers to aid in the diagnosis of breast cancer', Dis. Markers, Vol. 17, pp. 301-307.
50. Wulfkuhle, J. D., McLean, K. C., Paweletz, C.P. et al. (2001), 'New approaches to proteomic analysis of breast cancer', Proteomics, Vol. 1, pp. 1205-1215.
51. Ball, G., Mian, S., Holding, F. et al. (2002), 'An integrated approach utilizing artificial neural networks and SELDI mass spectrometry for the classification of human tumours and rapid identification of potential biomarkers', Bioinformatics, Vol. 18, pp. 395-404.
52. Vlahou, A., Schellhammer, P. F., Mendrinos, S. et al. (2001), 'Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine', Am. J. Pathol, Vol. 158, pp. 1491-1502.
53. Carter, D., Douglass, J. F., Cornellison, C. D. et al. (2002), 'Purification and characterization of the mammaglobin/lipophilin B complex, a promising diagnostic marker for breast cancer, Biochemistry, Vol. 41, pp. 6714-6722.
54. Sasaki, K., Sato, K., Akiyama, Y. et al. (2002), 'Peptidomics-based approach reveals the secretion of the 29-residue COOH-terminal fragment of the putative tumor suppressor protein DMBT1 from pancreatic adenocarcinoma cell lines', Cancer Res., Vol. 62, pp. 4894-4898.
55. Cazares, L. H., Adam, B. L., Ward, M. D. et al. (2002), 'Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry', Clin. Cancer Res., Vol. 8, pp. 2541-2552.
56. Cazares, L. H., Gong, L., Nasim, S. et al. (1999),' Surface enhanced laser desorption/ ionization (SELDI) mass spectroscopy for the discovery of prostate cancer signature proteins in laser capture microdissected cells', Proceedings of the 4th IBC International Conference on Functional Proteomics', San Diego, California, 1st-3rd December.
57. Petricoin, E. F. 3rd, Ornstein, D. K., Paweletz, C. P. et al. (2002), 'Serum proteomic patterns for detection of prostate cancer', J. Natl Cancer Inst., Vol. 94, pp. 1576-1578.